AAOS Roundup: Robotic Ortho Surgery Continues To Gain Traction, Led By Stryker's MAKO
Executive Summary
Stryker is enjoying strong demand for its MAKO robotic surgery platform with plans to increase system placements and procedure volumes while working on a next-gen system that would enhance ease-of-use for surgeons and improve accuracy. The company also has plans to expand into other areas of focus, according to analyst reports from this year's AAOS annual meeting in New Orleans. Meanwhile, Smith & Nephew and Zimmer Biomet are trying to set themselves apart with their robotic technologies.
You may also be interested in...
More Than Mako: Stryker Delivers Strong Growth In All Three Businesses
Stryker’s revenues grew 8.1% in 2019, its seventh consecutive year of accelerating organic growth and 40th year of sales growth. All three of the company’s major divisions grew in the high single-digits, led by sales of neurotechnology and spine products.
Mako Robot Sales Drive Stryker’s Orthopedics Business In Second Quarter
Stryker reported organic growth of 8.5% during the second quarter of 2019 led by 12% growth in the medical and surgical equipment business, 7% growth in neurotechnology and spine revenue, and 6% growth in sales of orthopedic devices, led by the Mako robotic surgery system.
AAOS 2019: OSSO VR Develops VR Training Tool For Smith & Nephew's NAVIO Robot, And More On Orthorobotics
Osso VR partnered with Smith & Nephew to develop a VR training tool that will be showcased at this year's American Association of Orthopedic Surgeons' (AAOS) conference, taking place in Las Vegas from March 12-16. Orthopedic robotic systems continue to draw high interest from surgeons. The recent US FDA clearance of Zimmer Biomet's ROSA total knee replacement system will add competition to the current market dominated by Stryker's MAKO and Smith & Nephew's NAVIO.